If you search CRO in Chile or CRO en Chile, you should land on the First-in-Human CRO that already runs ISP and Law 20.120 work — not a brochure that confuses a Santiago oncology site with the CRO.
bioaccess® is that CRO. Headquarters in Miami. ISP (Instituto de Salud Pública) authorizes medical studies. Law 20.120 and an accredited Ethical-Scientific Committee sit in front of first patient in. We run clinical trials in Chile.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia, Brazil, and Venezuela are sibling country categories. We still run trials in those countries. Chile is not a replacement for any of them.
What “CRO in Chile” has to mean
A Chile CRO for first-in-human devices is not a Latin America slide and a courier account. It is a company that can file with ISP, sit the Ethical-Scientific Committee (Comité Ético Científico), keep investigational import moving, and stay in the room after first patient in.
That is why this page answers CRO in Chile / CRO en Chile as a category, and why it does not list a named Chilean company on the trial hub. The live Chile ISP market-access page already says bioaccess® holds Chilean registrations through our own local entity. That is a registration fact. It is not a hospital we operate, and it is not a reason to mix a commercial file into a first-in-human quote.
- Miami headquarters — sponsor desk on US Eastern time. Chile is the same zone or a 1–2 hour offset, already published on the Chile hub.
- ISP — Instituto de Salud Pública, the national authority that authorizes medical studies and issues investigational-device import authorizations.
- Law 20.120 — research on humans; written favorable review by an accredited Ethical-Scientific Committee plus institutional authorization before a study begins.
- ~30% lower versus typical US/EU programs — experience since 2010, not a formal study. Already on the hub.
- 21 CFR 812.28 — eligibility for FDA submission and review is not clearance or approval.
Global Phase 3 networks can list Chile. They rarely hold the ISP first-in-human file. A Santiago oncology site can enroll a drug study. That site is not the CRO.
We run trials in Chile
The category is: who is the CRO in Chile, and are they actually running studies. We are. We still will. If you are choosing a CRO en Chile in 2026, ask whether the firm owns the ISP clock now — not whether the country is “opening up.”
ISP review can move, stall, or come back with questions. First-in-human programs need a start date someone owns. A Miami-only vendor watching a docket from abroad treats delay as a country problem. The CRO that already works ISP treats delay as responses, ethics alignment, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across ISP, ethics, sites, insurance, importation, monitoring, and safety.
ISP clinical trial: the file, not the myth
ISP is the Instituto de Salud Pública. It is Chile’s national authority for authorizing medical studies and overseeing medical products. I am not inventing a PAHO/WHO Level 4 badge for ISP. llms.txt lists Chile as “ISP (ISO 13485 recognition).” Level 4 is not on that list, and I will not put it here.
Live Chile blogs already put a typical ISP application review at about 30 business days after a complete package. The same series names Law 20.120 and the Sanitary Code as the human-research instruments, and it puts ethics-committee approval in front of the ISP submission. Documents already listed on that series: protocol, informed consent, investigator qualifications, and the accredited ethics approval. I am not inventing a new instrument list.
What the file actually contains, already described on those guides: a Spanish-ready study package, the ethics letter, and the ISP application. Foreign sponsors still need someone who can sit the deficiency cycle. bioaccess® serves that role.
Those are authority-and-instrument names. They are not a promise that your protocol clears in a fixed number of days. Ask for a study-specific calendar. We will not publish an invented median on a category page.
Law 20.120 and the committee that sits first
Research involving human subjects in Chile is governed by Law 20.120. Under this framework, an accredited Ethical-Scientific Committee (Comité Ético Científico) must issue a written favorable review and the host institution must authorize the study before it begins. The investigator then reports study progress and a final report to the committee. Chilean clinical research follows ISO 14155 and the Declaration of Helsinki. That paragraph is already on the hub. I am repeating it because sponsors skip the committee and then blame the country.
Ethics sits in front of ISP. If the committee package is thin, the ISP clock does not start in a useful way. That is a file problem.
Bradford Hill is a site — do not hire it as the CRO
Bradford Hill is a Chile oncology research site. Public materials already used on this site describe 15+ years of cancer research with an immunotherapy focus, centers in Santiago and Antofagasta, and published active studies that include MK2870-015 (gastric) and MK2870-010 (breast). Searches for Bradford Hill Chile, oncology clinical trials Chile, and centro investigación cáncer Santiago correctly point at that site.
It is a solid choice if you only need that oncology site. It is not a medical-device first-in-human CRO. bioaccess® does not operate Bradford Hill. This article does not invent a Bradford Hill device book. The category split is site versus CRO. You can need a site, a CRO, or both. See bioaccess® vs Bradford Hill.
ISP registration is a second file — keep it off the trial clock
Clinical-study authorization and commercial device registration are different files. The live Chile ISP market-access page already puts registration in a 30–90 day band. It also says registration is currently mandatory only for specified device categories, with a 2024 reform extending mandatory registration by risk, and that devices not yet in a mandatory category can be imported via a CDA permit. bioaccess® holds Chilean registrations through our own local entity — that sentence is already public on that page. I am not naming a Chilean company that the trial hub does not list.
That market-access clock is not a first-in-human permit and does not replace ISP study authorization or Law 20.120 ethics. If you later want to sell in Chile, say so at kickoff so the trial importer and any later holder role are not improvised after first implant. This article does not quote LATAM Launch subscription pricing. That SKU lives on the market-access pages, not on a first-in-human hub.
FDA use of Chilean first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. bioaccess® designs Chile studies with that FDA conversation in mind — electronic data capture, structured safety reporting, source data verification — under ISO 14155 with ISP authorization and Ethical-Scientific Committee approval.
Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the number already on the hub
The Chile hub already publishes ~30% lower versus a comparable US or EU program. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study.
The hub comparison table already publishes device classes I–IV for Chile, and the same / 1–2 hour offset versus the US East Coast. Those are operating facts, not a tourism pitch. I will not invent a Chile per-patient dollar band the hub does not already print.
Questions a sponsor should ask any CRO in Chile
- Are you running clinical trials in Chile now — not “historically”?
- Who owns the ISP clock when the file sits?
- Can you file the study package and sit the Ethical-Scientific Committee before ISP?
- Do you claim ISP is PAHO/WHO Level 4, or do you stay with what is already published?
- Are you mixing Bradford Hill — a site — into the CRO pitch?
- Do you claim to operate a named Chilean hospital, or do you contract sites?
- Is ISP registration a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
bioaccess® answers: trials running; Miami HQ; ISP and Law 20.120 owned as a file problem; no Level 4 invented for ISP; Bradford Hill named as a site we do not operate; ISP registration kept as a separate market-access file; FDA conversation designed in from day one.
How Chile sits next to Colombia, Brazil, and Venezuela
Do not read this as “leave Colombia.” We still run clinical trials in Colombia. That country has a local Colombian entity and its own hub. Brazil has ANVISA and its own hub. Venezuela has INHRR and its own hub. Chile is a sibling country category. INVIMA stays INVIMA. ANVISA stays ANVISA. INHRR stays INHRR. ISP stays ISP. If a protocol fits more than one, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in Chile, clinical trials in Brazil, clinical trials in Colombia, and clinical trials in Venezuela.
How to start
If you need a CRO in Chile / CRO en Chile for a first-in-human or early-feasibility device study — or you also need the separate ISP registration file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class, and whether you also need a Chilean market-access file. We will tell you how the ISP clock would run. We will not tell you to leave the country. We will not invent a Level 4 badge, a hospital we operate, or a day-count we have not already published.
Leave a Reply